Clinical

Dataset Information

0

Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma


ABSTRACT: Phase 1: Assessment of safety and tolerability of ADI-PEG 20 in combination with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) in advanced GI malignancies. Phase 2: Assessment of the objective response rate (ORR), measured by RECIST 1.1 criteria as assessed by blinded independent central review (BICR).

DISEASE(S): Carcinoma,Advanced Gastrointestinal (gi) Malignancies,Gastric Cancer,Colorectal Cancer,Carcinoma, Hepatocellular,Advanced Hepatocellular Carcinoma (hcc)in The Third Line Or Later Setting,Carcinoma Hepatocellular,Neoplasms,Hepatocellular Carcinoma

PROVIDER: 2163812 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2021-05-26 | GSE152457 | GEO
2021-05-26 | GSE152456 | GEO
2018-07-12 | GSE116922 | GEO
2018-05-28 | PXD009376 | Pride
| PRJNA639497 | ENA
| PRJNA639498 | ENA
| PRJNA639499 | ENA
| PRJNA639500 | ENA
2016-01-01 | GSE73106 | GEO
2016-07-03 | E-GEOD-73106 | biostudies-arrayexpress